Preventive Genetic Testing for Cancer Predisposition
Genetic testing is currently one of the most important tools for the prevention and early diagnosis of cancer. The identification of pathogenic mutations in genes associated with hereditary cancers allows for personalized surveillance, prevention, and the selection of appropriate therapeutic strategies. Genes such as BRCA1, BRCA2, TP53, APC, MLH1, and many others are linked to an increased risk of developing specific types of cancer.
The BRCA1 and BRCA2 genes are among the best-known cancer predisposition genes. Mutations in these genes significantly increase the risk of breast and ovarian cancer and are also associated with pancreatic and prostate cancer. Genetic testing in individuals with a family history of cancer enables more frequent mammograms, magnetic resonance imaging (MRI), and preventive interventions.
In colorectal cancer, particularly important genes include APC, MLH1, MSH2, MSH6, PMS2, and MUTYH. Mutations in MLH1, MSH2, MSH6, and PMS2 are associated with Lynch syndrome, which increases the risk of colorectal, endometrial, and other cancers. Early colonoscopy screening and close monitoring significantly reduce mortality.
The APC gene is associated with familial adenomatous polyposis, a condition in which hundreds of polyps develop in the intestine, often leading to cancer if not treated early. Similarly, the POLE and POLD1 genes are linked to an increased risk of polyposis and gastrointestinal cancers.
Other important genes include TP53, PTEN, STK11, and CDKN2A. TP53 is associated with Li-Fraumeni syndrome, which predisposes individuals to multiple types of cancer from a young age. PTEN is linked to Cowden syndrome and an increased risk of breast, thyroid, and endometrial cancer. STK11 is associated with Peutz-Jeghers syndrome, while CDKN2A increases the risk of melanoma and pancreatic cancer.
In neuroendocrine and endocrine tumors, genes such as MEN1, RET, SDHB, SDHC, SDHD, and TMEM127 are associated with pheochromocytoma, paragangliomas, and medullary thyroid cancer. Regular imaging and biochemical monitoring are critical for individuals carrying these mutations.
The genes VHL, FH, FLCN, and MET are associated with hereditary kidney cancers. Individuals with mutations in these genes may develop cysts, benign tumors, or aggressive renal cancers. Early diagnosis through MRI and ultrasound significantly improves the chances of successful treatment.
Other important genes include RUNX1, DDX41, CEBPA, and GATA2, which are associated with leukemias and myelodysplastic syndromes. In addition, NF1, NF2, SMARCB1, and SUFU are linked to tumors of the nervous system.
The use of multi-gene panels now allows the simultaneous analysis of dozens of genes, including AIP, ATM, AXIN2, BAP1, BMPR1A, CHEK2, DICER1, PALB2, RAD50, RAD51C, RAD51D, RECQL, WT1, and many others. Next-generation sequencing (NGS) technology has reduced costs while increasing the accuracy of testing.
Genetic testing is important not only for prevention but also for treatment. In certain cancers, the presence of specific mutations determines the use of targeted therapies, such as PARP inhibitors in patients with BRCA1 and BRCA2 mutations.
Understanding the genes responsible for hereditary cancers has transformed oncology. Proper genetic counseling, personalized surveillance, and early diagnosis can save lives and significantly improve the quality of life of patients and their families.
See the tests:
